MX2017014797A - Metodos y kits para tratar la depresion. - Google Patents
Metodos y kits para tratar la depresion.Info
- Publication number
- MX2017014797A MX2017014797A MX2017014797A MX2017014797A MX2017014797A MX 2017014797 A MX2017014797 A MX 2017014797A MX 2017014797 A MX2017014797 A MX 2017014797A MX 2017014797 A MX2017014797 A MX 2017014797A MX 2017014797 A MX2017014797 A MX 2017014797A
- Authority
- MX
- Mexico
- Prior art keywords
- kits
- methods
- treatment
- depression
- treating depression
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 1
- 206010042458 Suicidal ideation Diseases 0.000 abstract 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 229960000450 esketamine Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
- Steroid Compounds (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164026P | 2015-05-20 | 2015-05-20 | |
| PCT/US2016/033404 WO2016187491A1 (en) | 2015-05-20 | 2016-05-20 | Methods and kits for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014797A true MX2017014797A (es) | 2018-02-15 |
Family
ID=57320901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014797A MX2017014797A (es) | 2015-05-20 | 2016-05-20 | Metodos y kits para tratar la depresion. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160338977A1 (enExample) |
| EP (1) | EP3297618A4 (enExample) |
| JP (1) | JP2018515557A (enExample) |
| KR (1) | KR20180008634A (enExample) |
| CN (1) | CN107735081A (enExample) |
| AU (3) | AU2016263598A1 (enExample) |
| CA (1) | CA2986477A1 (enExample) |
| CL (1) | CL2017002904A1 (enExample) |
| CO (1) | CO2017011564A2 (enExample) |
| DO (1) | DOP2017000268A (enExample) |
| EA (1) | EA201792545A1 (enExample) |
| EC (1) | ECSP17077930A (enExample) |
| GT (1) | GT201700246A (enExample) |
| HK (1) | HK1252937A1 (enExample) |
| IL (1) | IL255463A (enExample) |
| MA (1) | MA42135A (enExample) |
| MX (1) | MX2017014797A (enExample) |
| PE (1) | PE20180260A1 (enExample) |
| PH (1) | PH12017502103A1 (enExample) |
| WO (1) | WO2016187491A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3813807A1 (en) * | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020070547A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| WO2020070706A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| WO2020178653A1 (en) * | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| CN114286674A (zh) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮 |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| IL293506A (en) | 2019-12-30 | 2022-08-01 | Clexio Biosciences Ltd | Dosage regime with esketamine for treating major depressive disorder |
| KR20230018448A (ko) * | 2020-05-28 | 2023-02-07 | 얀센 파마슈티카 엔.브이. | 우울증의 치료 방법 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| US20130236573A1 (en) * | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015512418A (ja) * | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| EP2983787B1 (en) * | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
| KR20170054470A (ko) * | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
-
2016
- 2016-05-19 US US15/159,257 patent/US20160338977A1/en not_active Abandoned
- 2016-05-20 AU AU2016263598A patent/AU2016263598A1/en not_active Abandoned
- 2016-05-20 KR KR1020177036002A patent/KR20180008634A/ko not_active Withdrawn
- 2016-05-20 EP EP16797348.6A patent/EP3297618A4/en not_active Withdrawn
- 2016-05-20 PE PE2017002425A patent/PE20180260A1/es unknown
- 2016-05-20 EA EA201792545A patent/EA201792545A1/ru unknown
- 2016-05-20 WO PCT/US2016/033404 patent/WO2016187491A1/en not_active Ceased
- 2016-05-20 HK HK18112292.0A patent/HK1252937A1/zh unknown
- 2016-05-20 MA MA042135A patent/MA42135A/fr unknown
- 2016-05-20 CA CA2986477A patent/CA2986477A1/en not_active Abandoned
- 2016-05-20 JP JP2017560314A patent/JP2018515557A/ja active Pending
- 2016-05-20 CN CN201680029082.XA patent/CN107735081A/zh active Pending
- 2016-05-20 MX MX2017014797A patent/MX2017014797A/es unknown
-
2017
- 2017-11-06 IL IL255463A patent/IL255463A/en unknown
- 2017-11-14 CO CONC2017/0011564A patent/CO2017011564A2/es unknown
- 2017-11-15 CL CL2017002904A patent/CL2017002904A1/es unknown
- 2017-11-16 GT GT201700246A patent/GT201700246A/es unknown
- 2017-11-17 DO DO2017000268A patent/DOP2017000268A/es unknown
- 2017-11-20 PH PH12017502103A patent/PH12017502103A1/en unknown
- 2017-11-23 EC ECIEPI201777930A patent/ECSP17077930A/es unknown
-
2021
- 2021-08-11 AU AU2021215155A patent/AU2021215155A1/en not_active Abandoned
-
2023
- 2023-09-25 AU AU2023237026A patent/AU2023237026A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160338977A1 (en) | 2016-11-24 |
| GT201700246A (es) | 2019-07-29 |
| PE20180260A1 (es) | 2018-02-05 |
| EA201792545A1 (ru) | 2018-05-31 |
| WO2016187491A1 (en) | 2016-11-24 |
| PH12017502103A1 (en) | 2018-05-07 |
| IL255463A (en) | 2018-01-31 |
| AU2016263598A1 (en) | 2017-11-23 |
| CN107735081A (zh) | 2018-02-23 |
| MA42135A (fr) | 2018-03-28 |
| CO2017011564A2 (es) | 2018-04-19 |
| DOP2017000268A (es) | 2018-04-15 |
| JP2018515557A (ja) | 2018-06-14 |
| AU2021215155A1 (en) | 2021-09-02 |
| EP3297618A1 (en) | 2018-03-28 |
| KR20180008634A (ko) | 2018-01-24 |
| AU2016263598A8 (en) | 2017-11-30 |
| AU2023237026A1 (en) | 2023-10-12 |
| HK1252937A1 (zh) | 2019-06-06 |
| CL2017002904A1 (es) | 2018-04-20 |
| ECSP17077930A (es) | 2018-02-28 |
| EP3297618A4 (en) | 2019-01-23 |
| CA2986477A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502103A1 (en) | Methods and kits for treating depression | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MX2023008760A (es) | Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| EA201792649A1 (ru) | Способы кондиционирования пациентов для t-клеточной терапии | |
| MX2018008346A (es) | Terapia de combinación de virus oncológico e inhibidor de punto de control. | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12021550448A1 (en) | Chronic nightly dosing of lasmiditan for migraine prevention. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MD4710B1 (ro) | Tratamente terapeutice pe bază de anamorelin | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| PH12017500275A1 (en) | Methods of treating depression using nmda modulators | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| AR105701A1 (es) | Métodos y estuches para tratar la depresión | |
| MX2019003002A (es) | Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer. | |
| GB2546703A (en) | Compounds |